Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
American Society of Clinical Oncology (ASCO)
Online
2023-04-19
DOI
10.1200/jco.22.01792
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Utilizing restricted mean duration of response for efficacy evaluation of cancer treatments
- (2022) Bo Huang et al. PHARMACEUTICAL STATISTICS
- Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma
- (2022) Petros Grivas et al. EUROPEAN UROLOGY
- Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
- (2021) Thomas Powles et al. LANCET ONCOLOGY
- The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma
- (2021) Richard Cathomas et al. EUROPEAN UROLOGY
- Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- (2021) T. Powles et al. ANNALS OF ONCOLOGY
- Current Treatment and Outcomes Benchmark for Locally Advanced or Metastatic Urothelial Cancer From a Large UK-Based Single Centre
- (2020) Sue Cheeseman et al. Frontiers in Oncology
- Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer
- (2020) Matthew D. Galsky et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
- (2020) Matthew D Galsky et al. LANCET
- Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
- (2020) Thomas Powles et al. LANCET ONCOLOGY
- Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
- (2020) Thomas Powles et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment patterns and overall survival in metastatic urothelial carcinoma in a real-world, US setting
- (2019) Jason C. Simeone et al. Cancer Epidemiology
- A Real-World Data Study to Evaluate Treatment Patterns, Clinical Characteristics and Survival Outcomes for First- and Second-Line Treatment in Locally Advanced and Metastatic Urothelial Cancer Patients in Germany
- (2018) Günter Niegisch et al. Journal of Cancer
- Evaluating Treatment Effect Based on Duration of Response for a Comparative Oncology Study
- (2018) Bo Huang et al. JAMA Oncology
- Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2–Positive Metastatic Bladder Cancer
- (2017) Thomas Powles et al. JOURNAL OF CLINICAL ONCOLOGY
- Empirical shrinkage estimator for consistency assessment of treatment effects in multi-regional clinical trials
- (2012) Hui Quan et al. STATISTICS IN MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now